Table 1.
Participant Demographics and Clinical Characteristics
| Overall | AR+ (range) | AR− (range) | p-value | |
|---|---|---|---|---|
| Sample Size | 94 | 48 | 46 | |
| Age (years) | 35 | 34 (23–39) | 35 (21–51) | > 0.10 |
| Sex (male) | 92% | 96% | 88% | > 0.10 |
| Ethnicity (non-Caucasian) | 37% | 38% | 37% | > 0.10 |
| Education (years) | 12 | 12 (9–20) | 12 (6–18) | > 0.10 |
| Duration of HIV (years) | 5.3 | 8.1 (.052–16.4) | 4.1 (0–16.9) | < 0.01 |
| HIV RNA, CSF (log10 c/mL)* | 2.9 | 2.6 (1.7–4.4) | 3.3 (1.7–6.2) | < 0.01 |
| HIV RNA, Plasma (log10 c/mL) | 4.7 | 4.4 (2.8–6) | 4.8 (3.3–6.3) | < 0.05 |
| CD4 Count, Current (/μL) | 319 | 340 (4–1188) | 308 (3–1296) | > 0.10 |
| CD4 Count, Nadir (/μL) | 216 | 200 (0–772) | 269 (0–1296) | > 0.10 |
| AIDS Diagnosis | 47% | 50% | 43% | > 0.10 |
| Past ARV Use | 63% | 73% | 51% | < 0.05 |
| Current ARV Use | 29% | 50% | 7% | < 0.001 |
| −Adherence (<95% in 4 weeks) | 53% | 50% | 75% | > 0.10 |
| HCV Seropositive | 25% | 25% | 24% | > 0.10 |
| Methamphetamine Abuse Ever | 57% | 51% | 63% | > 0.10 |
Values are medians or proportions; n = 94;
*
subgroup analysis
P-values are based on univariate analyses. Individuals with drug resistance (AR+) differed from those with no drug resistance (AR−) in duration of HIV infection, CSF HIV RNA, plasma HIV RNA, past antiretroviral (ARV) use, and current ARV use.